Janelle Zeihen worried she'd have to file for bankruptcy after learning she owed $250,000 for her Crohn's disease treatment.

AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, ...

Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks ...

AbbVie may be setting its sights on 2026, but analysts are already smitten with its present-day promise. Cantor Fitzgerald ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

Analysts on Wall Street project that AbbVie (ABBV) will announce quarterly earnings of $2.40 per share in its forthcoming report, representing an increase of 3.9% year over year. Revenues are ...

The first-quarter 2025 earnings season for the Medical sector is about to pick up pace this week. The sector mainly comprises ...

Galapagos (Euronext: GLPG) has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a ...

The first quarter of 2025 will be remembered for rapid change. U.S. presidential transitions typically focus on achieving one ...

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...